Best in Class Oncology and Hematology Care.
Patient Centered. Physician-involved.
When you refer a patient to Cancer Centers of Florida, you can expect nothing less than compassionate patient-centered care from a staff dedicated to providing excellent cancer treatment and support services. You can use our referral form to request an appointment.
Our practice of skilled physicians offers a consultative, multi-specialty team approach. Our foundatin of medical and radiation oncology expertise with hematology care in addition, is enhanced by specific experience with nearly every cancer type.
While our focus is on the patient, we understand the importance of keeping you , the referring physician, up-to-date on your patient's progress and treatment plan.
When you refer a patient to Cancer Centers of Florida, you can expect that we'll provide:
- An appointment within 24-48 hours, upon authorization.
- Timely reporting of clinical findings and results.
- Peer-to-peer consultations.
- Access to clinical trials.
- Access to clinical pathways.
- Convenient office access.
Cancer in the News
- Generic Versions Of Blood Thinning Plavix Approved By FDA
- Discovery Alters Prevailing View Of Splicing Regulation And Has Implications For Splicing Mutations Associated With Disease
- Hormone-Depleting Drug Shows Promise Against Localized High-Risk Prostate Tumors
- New National Guidelines For Treatment Of Subarachnoid Hemorrhage
- Trial Of ALK Inhibitor In Neuroblastoma, Lymphoma
- Older People With Chronic Leukemia May Benefit From Experimental Agent
- Personalized Treatment Advances: Testing For Mutations Identified In Squamous Cell Lung Cancer Tumors
- Patients With Muscle-Invasive Bladder Cancer Benefit From Accelerated Chemotherapy Given Before Surgery
- Glioblastoma Classification Revision Should Improve Patient Care
- Minimal Residual Disease Detected In Nearly Double The Number Of Leukemia Patients Using High-Throughput Sequencing
- The Cause Identified Of LGL Leukemia
- Make Or Break For Cellular Tissues
- Lapatinib Combined With Cetuximab Overcomes Resistance In EGFR-Driven Tumors
- Positive Survival Trend Seen In Phase I Study Of Temsirolimus, Capecitabine



